Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.35 |
| ▸ | DRD4 | P21917 | 2/20 | 0.35 |
| ▸ | DRD3 | P35462 | 2/20 | 0.35 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.33 |
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1359746 | 0.85 | USP30 (0.49) | USP30KMT2A | |
| SCHEMBL25354957 | 0.85 | DRD2 (0.34) | DRD2DRD4DRD3UCHL1ALOX15 | |
| SCHEMBL1357539 | 0.81 | UCHL1 (0.33) | DRD2DRD4DRD3UCHL1 | |
| SCHEMBL1357537 | 0.81 | UCHL1 (0.33) | DRD2DRD4DRD3UCHL1 | |
| SCHEMBL29339990 | 0.81 | USP30 (0.52) | USP30 | |
| SCHEMBL17102312 | 0.80 | LRRK2 (0.38) | — | |
| SCHEMBL1359373 | 0.79 | ALOX15 (0.32) | DRD2DRD4DRD3UCHL1ALOX15 | |
| SCHEMBL11961447 | 0.79 | CHRNB2 (0.41) | DRD2DRD4DRD3UCHL1KMT2A | |
| SCHEMBL1359375 | 0.79 | ALOX15 (0.32) | DRD2DRD4DRD3UCHL1ALOX15 | |
| SCHEMBL1358468 | 0.77 | UCHL1 (0.43) | UCHL1KMT2AALDH1A1KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2569314-B1 | FUSED BICYCLIC KINASE INHIBITORS | OSI PHARMACEUTICALS LLC (US) | 2016-09-07 | — | — | EP | disclosed |
| US-20130253197-A1 | FUSED BICYCLIC KINASE INHIBITORS | OSI Pharmaceuticals, LLC (US) | 2013-09-26 | — | — | US | disclosed |
| US-8445510-B2 | Fused bicyclic kinase inhibitors | OSI Pharmaceuticals, LLC (US) | 2013-05-21 | — | — | US | disclosed |
| EP-2569314-A1 | FUSED BICYCLIC KINASE INHIBITORS | OSI Pharmaceuticals, LLC (US) | 2013-03-20 | — | — | EP | disclosed |
| US-20110281888-A1 | Fused Bicyclic Kinase Inhibitors | OSI Pharmaceuticals, LLC | 2011-11-17 | — | — | US | disclosed |
| WO-2011143645-A1 | FUSED BICYCLIC KINASE INHIBITORS | OSI Pharmaceuticals, LLC (US) | 2011-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281888-A1 | Fused Bicyclic Kinase Inhibitors | ALK, RET, MET | DRD2 3717/4885DRD4 4417/4885DRD3 3830/4885 |
| US-20130253197-A1 | FUSED BICYCLIC KINASE INHIBITORS | ALK, RET, MET | DRD2 3717/4885DRD4 4417/4885DRD3 3830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.